Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur J Hum Genet. 2014 Nov;22(11):1305-13. doi: 10.1038/ejhg.2014.16. Epub 2014 Feb 19.

Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.

Author information

1
1] Department of Cancer Biology and Genetics, CLCC François Baclesse, Caen, France [2] Inserm U1079, Rouen, France.
2
1] Department of Cancer Biology and Genetics, CLCC François Baclesse, Caen, France [2] Inserm U1079, Rouen, France [3] Department of Biochemistry and Toxicology, Caen University, Caen, France.
3
Department of Cancer Biology and Genetics, CLCC François Baclesse, Caen, France.
4
1] Inserm U1079, Rouen, France [2] Department of Genetics, University Hospital, Rouen, France.
5
Department of Genetics, University Hospital, Fort-de-France, France.
6
Department of Genetics, University Hospital, Rennes, France.
7
Department of Genetics, CLCC François Baclesse, Caen, France.
8
Department of Genetics, Jacques Monod Hospital, Le Havre, France.
9
1] Inserm U1079, Rouen, France [2] Department of Genetics, University Hospital, Rouen, France [3] Rouen University, IRIB, Rouen, France.

Abstract

To optimize the molecular diagnosis of hereditary breast and ovarian cancer (HBOC), we developed a next-generation sequencing (NGS)-based screening based on the capture of a panel of genes involved, or suspected to be involved in HBOC, on pooling of indexed DNA and on paired-end sequencing in an Illumina GAIIx platform, followed by confirmation by Sanger sequencing or MLPA/QMPSF. The bioinformatic pipeline included CASAVA, NextGENe, CNVseq and Alamut-HT. We validated this procedure by the analysis of 59 patients' DNAs harbouring SNVs, indels or large genomic rearrangements of BRCA1 or BRCA2. We also conducted a blind study in 168 patients comparing NGS versus Sanger sequencing or MLPA analyses of BRCA1 and BRCA2. All mutations detected by conventional procedures were detected by NGS. We then screened, using three different versions of the capture set, a large series of 708 consecutive patients. We detected in these patients 69 germline deleterious alterations within BRCA1 and BRCA2, and 4 TP53 mutations in 468 patients also tested for this gene. We also found 36 variations inducing either a premature codon stop or a splicing defect among other genes: 5/708 in CHEK2, 3/708 in RAD51C, 1/708 in RAD50, 7/708 in PALB2, 3/708 in MRE11A, 5/708 in ATM, 3/708 in NBS1, 1/708 in CDH1, 3/468 in MSH2, 2/468 in PMS2, 1/708 in BARD1, 1/468 in PMS1 and 1/468 in MLH3. These results demonstrate the efficiency of NGS in performing molecular diagnosis of HBOC. Detection of mutations within other genes than BRCA1 and BRCA2 highlights the genetic heterogeneity of HBOC.

PMID:
24549055
PMCID:
PMC4200427
DOI:
10.1038/ejhg.2014.16
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center